This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Novo Nordisk Cuts Wegovy Price in India
Business price cut

Novo Nordisk Cuts Wegovy Price in India

Analysis based on 6 articles · First reported Nov 11, 2025 · Last updated Nov 12, 2025

Sentiment
20
Attention
6
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The price cut by Novo Nordisk for Semaglutide in India is expected to intensify competition in the weight-loss drug market, potentially leading to lower prices across the board and increased accessibility for consumers. This move directly impacts the market share and profitability of Novo Nordisk and Eli Lilly and Company, as well as future generic drugmakers like Abbott Laboratories, Sun Pharma, Mankind Pharma, and Natco Pharma.

Pharmaceuticals Healthcare
Event Summary

Novo Nordisk has significantly cut the price of its weight-loss drug, Semaglutide, by up to 37% in India. This strategic move aims to boost sales and gain market share against its rival, Eli Lilly and Company's Tirzepatide, which has become India's top-selling weight-loss drug. The price reduction also comes ahead of Semaglutide's active ingredient, semaglutide, going off-patent in India in March 2026, which will allow generic drugmakers such as Abbott Laboratories, Sun Pharma, Mankind Pharma, and Natco Pharma to enter the market. Novo Nordisk India's Managing Director, Vikrant Shrotriya, stated that the price revision is intended to make the medication more accessible to people living with obesity in India. Both Novo Nordisk and Eli Lilly and Company have also formed partnerships with local pharmaceutical firms, Emcure Pharmaceuticals and Cipla respectively, to expand the distribution of their drugs in the crucial Indian market.

Entities Involved
stock
Novo Nordisk
Novo Nordisk cut the price of its weight-loss drug Semaglutide in India to compete with Eli Lilly and prepare for generic competition, aiming to increase market share and accessibility.
Importance 100.0 Sentiment 30.0
stock
Eli Lilly and Company
Eli Lilly and Company's drug Tirzepatide has been a strong competitor to Semaglutide in India, prompting Novo Nordisk to cut prices. Eli Lilly and Company has gained significant market share.
Importance 80.0 Sentiment 10.0
cnt
India
India is a key battleground for weight-loss drugs due to its large obesity population and is experiencing significant competition between Novo Nordisk and Eli Lilly and Company.
Importance 70.0 Sentiment 10.0
per
Vikrant Shrotriya
Vikrant Shrotriya, Managing Director of Novo Nordisk India, stated that the price revision aims to make Semaglutide more accessible to people in India.
Importance 40.0 Sentiment 10.0
priv
Emcure Pharmaceuticals
Novo Nordisk partnered with Emcure Pharmaceuticals to distribute Semaglutide under the Poviztra brand name in India, aiming to expand market access.
Importance 30.0 Sentiment 10.0
stock
Cipla
Eli Lilly and Company has partnered with Cipla to market Tirzepatide in India, aiming to widen its distribution.
Importance 25.0 Sentiment 10.0
stock
Mankind Pharma
Mankind Pharma is an Indian generic drugmaker preparing to enter the market with generic versions of semaglutide.
Importance 20.0 Sentiment 5.0
stock
Natco Pharma
Natco Pharma is one of the Indian generic drugmakers that will likely offer lower-priced versions of semaglutide once the patent expires.
Importance 20.0 Sentiment 5.0
stock
Sun Pharma
Sun Pharma is among the Indian generic drugmakers expected to introduce lower-priced versions of semaglutide after Semaglutide's patent expires.
Importance 20.0 Sentiment 5.0
stock
Abbott Laboratories
Abbott Laboratories is one of several Indian generic drugmakers poised to enter the market with lower-priced versions of semaglutide once Semaglutide loses patent exclusivity.
Importance 20.0 Sentiment 5.0
priv
Pharmarack
Pharmarack is a market research firm that provided data on the sales performance of Tirzepatide and Semaglutide in India.
Importance 10.0 Sentiment 0.0
per
Vishal Manchanda
Vishal Manchanda, an analyst at Nuvama Institutional Equities, suggested that the price cut by Novo Nordisk could be a strategy to compete better with Tirzepatide and against future generics.
Importance 5.0 Sentiment 0.0
per
Amar Vennapusa
Amar Vennapusa, a bariatric surgeon, commented that the price cut by Novo Nordisk appears to be a move to better compete with Tirzepatide in India's price-sensitive market.
Importance 5.0 Sentiment 0.0
priv
Nuvama Institutional Equities
Nuvama Institutional Equities analyst Vishal Manchanda commented on the potential reasons for Novo Nordisk's price cut, including competition and upcoming generic entry.
Importance 5.0 Sentiment 0.0
Relationships
Novo Nordisk related ↔ Eli Lilly and Company
Novo Nordisk related ↔ India
India related ↔ Natco Pharma
India related ↔ Sun Pharma
India related ↔ Abbott Laboratories
Sun Pharma competitor ↔ Abbott Laboratories Sun Pharmaceutical Industries acts as a major competitor to Abbott Laboratories across various therapeutic segments and
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.